Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Venetoclax

FDA-approved product (tablet, oral), marketed as Venclexta, Venetoclax.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Venetoclax
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chronic lymphocytic leukemia
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antineoplastic agents
FDA pharmacologic class
BCL-2 Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae45.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Venetoclax in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Venetoclax with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

    NCT06514261 · start 2024-12-18

    Registered record
    Registry ID
    NCT06514261
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Azacitidine; Biospecimen Collection; Biospecimen Collection; Bone Marrow Aspiration; Buccal Swab; Iadademstat; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Suspended
    Start
    2024-12-18
    Completion
    2027-09-16
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionAzacitidine; Biospecimen Collection; Biospecimen Collection; Bone Marrow Aspiration +3 more
    PhasePhase 1
    Registry statusSuspended

  • The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation

    NCT06561880 · start 2024-10-08

    Registered record
    Registry ID
    NCT06561880
    Conditions
    FLT3 Gene Mutation; AML
    Interventions
    Venetoclax; Cytarabine; Gilteritinib; Azacitadine (AZA)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-10-08
    Completion
    2027-08-31
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFLT3 Gene Mutation; AML
    InterventionVenetoclax; Cytarabine; Gilteritinib; Azacitadine (AZA)
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

    NCT06115135 · start 2024-06-20

    Registered record
    Registry ID
    NCT06115135
    Conditions
    Multiple Myeloma in Relapse; Multiple Myeloma, Refractory
    Interventions
    Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-06-20
    Completion
    2027-12-31
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma in Relapse; Multiple Myeloma, Refractory
    InterventionVenetoclax
    PhasePhase 2
    Registry statusRecruiting

  • Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia

    NCT06537843 · start 2023-12-01

    Registered record
    Registry ID
    NCT06537843
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Venetoclax; Cytarabine Injection; Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-12-01
    Completion
    2028-07-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionVenetoclax; Cytarabine Injection; Metformin
    PhasePhase 2
    Registry statusRecruiting

  • Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms

    NCT05074355 · start 2023-11-08

    Registered record
    Registry ID
    NCT05074355
    Conditions
    Myeloproliferative Neoplasm
    Interventions
    Azacitidine; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-11-08
    Completion
    2026-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyeloproliferative Neoplasm
    InterventionAzacitidine; Venetoclax
    PhasePhase 2
    Registry statusRecruiting

  • Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients

    NCT06073730 · start 2023-11-01

    Registered record
    Registry ID
    NCT06073730
    Conditions
    Elderly AML Patients; Unfit, New-diagnosis AML; Acute Myeloid Leukemia; Venetoclax; Decitabine
    Interventions
    Experimental: Venetoclax in combination with Decitabine (+-sorafenib); Active Comparator: Standard dose of Venetoclax + Azacitidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-11-01
    Completion
    2026-04-30
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionElderly AML Patients; Unfit, New-diagnosis AML; Acute Myeloid Leukemia; Venetoclax +1 more
    InterventionExperimental: Venetoclax in combination with Decitabine (+-sorafenib); Active Comparator: Standard dose of Venetoclax + Azacitidine
    PhasePhase 3
    Registry statusCompleted

  • Venetoclax After TKI to Target Persisting Stem Cells in CML

    NCT05701215 · start 2023-08-31

    Registered record
    Registry ID
    NCT05701215
    Conditions
    Chronic Myeloid Leukemia
    Interventions
    Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-08-31
    Completion
    2026-05-31
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia
    InterventionVenetoclax
    PhasePhase 2
    Registry statusCompleted

  • Implantable Microdevice for TNBC - Pilot Study

    NCT05774886 · start 2023-05

    Registered record
    Registry ID
    NCT05774886
    Conditions
    Triple Negative Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Breast Cancer; Early Stage Triple-Negative Breast Carcinoma; Breast Neoplasms; Breast Carcinoma
    Interventions
    Implantable Microdevice (IMD)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2023-05
    Completion
    2028-09-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTriple Negative Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Breast Cancer +3 more
    InterventionImplantable Microdevice (IMD)
    PhasePhase 1
    Registry statusWithdrawn

  • Venetoclax Basket Trial for High Risk Hematologic Malignancies

    NCT05292664 · start 2023-03-29

    Registered record
    Registry ID
    NCT05292664
    Conditions
    Myelodysplastic Syndromes, de Novo; Myelodysplastic Syndromes, Secondary; Myelodysplastic Syndromes, Previously Treated; Treatment-Related Acute Myeloid Leukemia; Therapy-Related Myelodysplastic Syndrome; Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia With Failed Remission; Lymphoblastic Lymphoma, in Relapse; Lymphoblastic Lymphoma, Refractory; Acute Leukemia of Ambiguous Lineage in Relapse; Acute Leukemia of Ambiguous Lineage
    Interventions
    Venetoclax; Azacitidine; Cytarabine; Methotrexate; Hydrocortisone; Leucovorin; Dexamethasone; Vincristine; Doxorubicin; Dexrazoxane; Calaspargase Pegol; Erwinia asparaginase
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2023-03-29
    Completion
    2030-07-02
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelodysplastic Syndromes, de Novo; Myelodysplastic Syndromes, Secondary; Myelodysplastic Syndromes, Previously Treated; Treatment-Related Acute Myeloid Leukemia +7 more
    InterventionVenetoclax; Azacitidine; Cytarabine; Methotrexate +8 more
    PhasePhase 1
    Registry statusRecruiting

  • Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia

    NCT06068621 · start 2023-03-01

    Registered record
    Registry ID
    NCT06068621
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Azacytidine; Cytarabine; Aclacinomycin; Chidamide; Venetoclax; Granulocyte colony-stimulating factor; "3+7"
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-03-01
    Completion
    2025-08-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionAzacytidine; Cytarabine; Aclacinomycin; Chidamide +3 more
    PhasePhase 2
    Registry statusCompleted

  • A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia

    NCT05736965 · start 2023-02-20

    Registered record
    Registry ID
    NCT05736965
    Conditions
    AML, Adult
    Interventions
    Selinexor; Azacitidine; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-02-20
    Completion
    2027-04-30
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAML, Adult
    InterventionSelinexor; Azacitidine; Venetoclax
    PhasePhase 2
    Registry statusRecruiting

  • Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia

    NCT05870995 · start 2023-02-01

    Registered record
    Registry ID
    NCT05870995
    Conditions
    Refractory Leukemia
    Interventions
    CALGE-VEN- RIC-conditioning
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-02-01
    Completion
    2026-09-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRefractory Leukemia
    InterventionCALGE-VEN- RIC-conditioning
    PhasePhase 2
    Registry statusRecruiting

  • AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

    NCT05209152 · start 2022-11-14

    Registered record
    Registry ID
    NCT05209152
    Conditions
    Higher Risk Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia
    Interventions
    AMG 176; Azacitidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2022-11-14
    Completion
    2023-12-19
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigher Risk Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia
    InterventionAMG 176; Azacitidine
    PhasePhase 1
    Registry statusTerminated

  • A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    NCT05057494 · start 2022-09-12

    Registered record
    Registry ID
    NCT05057494
    Conditions
    Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Interventions
    Acalabrutinib; Venetoclax; Obinutuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2022-09-12
    Completion
    2029-04-10
    Enrolment
    607

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    InterventionAcalabrutinib; Venetoclax; Obinutuzumab
    PhasePhase 3
    Registry statusActive not recruiting

  • Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

    NCT05522192 · start 2022-07-21

    Registered record
    Registry ID
    NCT05522192
    Conditions
    Relapsed or Refractory Acute Myeloid Leukemia
    Interventions
    Mitoxantrone liposome; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2022-07-21
    Completion
    2026-05
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed or Refractory Acute Myeloid Leukemia
    InterventionMitoxantrone liposome; Venetoclax
    PhasePhase 1 / Phase 2
    Registry statusUnknown